Myelin pp 311-335 | Cite as

The Neurology of Myelin Diseases

  • Ute Traugott
  • Cedric S. Raine


The myelin diseases are a heterogeneous group, the clinical manifestations of which are exceedingly varied and include a wide spectrum of neurological symptoms. Since there is no common mode of presentation and the courses are so different, it is impossible to make sweeping generalizations that apply to all the conditions covered in this chapter. Each must be considered as a distinct clinical entity (see Table I for a brief classification).


Multiple Sclerosis Phytanic Acid Optic Neuritis Pernicious Anemia Acute Disseminate Encephalomyelitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abramsky, O., Lisak, R. P., Silberberg, D. H., and Pleasure, D. E., 1977, Antibodies to oligodendroglia in patients with multiple sclerosis, N. Engt. J. Med. 297: 1207.CrossRefGoogle Scholar
  2. Adachi, M., Schnuck, L., Cara, J., and Volk, B. W., 1973, Spongy degeneration of the central nervous system (van Bogaert and Bertrand type; Canavan’s disease): A review, Ruin. Pathol. 4: 331.Google Scholar
  3. Adams, R. D., Festenstein, H., Gibson, J. D., Hughes, R. A. C., Jaraquemada, J., Papasteriadis, C., Sachs, J., and “Thomas, P. K., 1979, HI.A antigens in chronic relapsing idiopathic inflammatory polyneuropathy, J. Neurol. Neurosurg. Psychiatry 42: 184.Google Scholar
  4. Adams, R. D., Victor, M., and Mancall, E. L., 1959, Central pontine myelinolysis, Arch. Neurol. Psychiatry 81: 184.CrossRefGoogle Scholar
  5. Armentrout, S. A., Sweet, P. M., and Galant, S. P., 1981, The effect of a factor from multiple sclerosis serum on isolated T and B lymphocytes, J. Clin. Lab. Immunol. 5: 133.PubMedGoogle Scholar
  6. Amason, B. G. W., 1973, Optic neuritis and multiple sclerosis, N. Engl. J. Med. 239: 1180.Google Scholar
  7. Amason, B. G. W., and Antel, j., 1978, Suppressor cell function in multiple sclerosis, Ann. Immunol. (Inst. Pasteur) 129c: 159.Google Scholar
  8. Arnon, R., Crisp, E., Kelley, R., Ellison, G. W., Myers, L. W., and ‘Tourtellotte, W. W., 1980, Antiganglioside antibodies in multiple sclerosis, J. Neurol. Sei. 46: 179.CrossRefGoogle Scholar
  9. Asbury, A. K., Amason, G. B., and Adams, R. D., 1969, The inflammatory lesion in idiopathic polyneuritis: Its role in pathogenesis, Medicine 48: 173.PubMedCrossRefGoogle Scholar
  10. Austin, J. H., 1968, Recurrent polyneuropathies and their corticosteroid treatment, Brain 81:157. Austin, J. II., 1973, Studies in metachromatic leukodystrophy. XII. Multiple sulfatase deficiency, Arch. Neurol. 28: 258.Google Scholar
  11. Bamford, C. R., Sibley, W. A., Thies, C., Laguna, J. F., Smith, M. S., and Clark, K., 1981, Trauma as an etiologic and aggravating factor in multiple sclerosis, Neurology 31: 1229.PubMedCrossRefGoogle Scholar
  12. Banker, B. Q., Robertson, J. T., and Victor, M., 1964, Spongy degeneration of the central nervous system in infancy, Neurology 14: 981.PubMedCrossRefGoogle Scholar
  13. Bashir, R. M., and Whitaker, J. N., 1980, Molecular features of immunoreactive myelin basic protein in cerebrospinal fluid of persons with multiple sclerosis, Ann. Neurol. 7: 50.PubMedCrossRefGoogle Scholar
  14. Basten, A., Pollard, J. D., Stewart, G. J., Frith, J. A., McLeod, J. G., Walsh, J. C., Garrick, R., and Van Der Brink, C. M., 1980, Transfer factor in treatment of multiple sclerosis, Lancet 2: 931.PubMedCrossRefGoogle Scholar
  15. Baum, H. M., and Rothschild, B. B., 1981, The incidence and prevalance of reported multiple sclerosis, Ann. Neurol. 10: 420.PubMedCrossRefGoogle Scholar
  16. Bertrams, J., and Kuwert, E., 1972, HL-A antigen frequencies in multiple sclerosis, Fur. Neurol. 7:74.Bird, T. D., 1975, Apparent familial multiple sclerosis in three generations, Arch. Neurol. 32: 414.Google Scholar
  17. Blaw, M. E., 1970, Melanodermic type leukodystrophy (adreno-leukodystrophy), in: Handbook of Clinical Neurology, Vol. 10 ( P. J. Vinken and G. W. Bruyn, eds.), pp. 128–133, North-Holland, Amsterdam.Google Scholar
  18. Bornstein, M. B., Miller, A. I., Teitelbaum, D., Arnon, R., and Sela, M., 1982, Multiple sclerosis: Trial of a synthetic polypeptide, Ann. Neurol. 11: 317.PubMedCrossRefGoogle Scholar
  19. Bradley, W. G., 1975, Disorders of Peripheral Nerves, Blackwells, Oxford.Google Scholar
  20. Carson, J. H., Barbarese, E., Braun, P. E., and McPherson, T. A., 1978, Components in multiple sclerosis cerebrospinal fluid that are detected by radioimmunoassay for myelin basic protein, Proc. Natl. Acad. Sci. U.S.A. 75: 1976.PubMedCrossRefGoogle Scholar
  21. Casey, B. R., Wong, S. T., Mason, A. J., Lee, R., and Ford, H. C., 1981, The electrophoretic demonstration of unique oligoclonal immunoglobulins in cerebrospinal fluid as a diagnostic test for multiple sclerosis, Clin. Chim. Acta 114: 187.PubMedCrossRefGoogle Scholar
  22. Cashman, N., Bach, M.-A., Martin, C., Degos, J.-D., and Bach, J. F., 1982, Suppressor/cytotoxic cell perturbation during exacerbations in MS, Neurology 32: A69.CrossRefGoogle Scholar
  23. Chiappa, K. H., 1980, Pattern shift visual, brainstem auditory and short latency somatosensory evoked potentials in multiple sclerosis, Neurology 30: 110.PubMedCrossRefGoogle Scholar
  24. Cohen, S. R., Brooks, B. R., Herndon, R. M., and Khann, G. M., 1980, A diagnostic index of active demyelination: Myelin basic protein in cerebrospinal fluid, Ann. Neural. 8: 25.CrossRefGoogle Scholar
  25. Compston, N. D., 1951, Disseminated sclerosis and angioneurotic edema, Proc. R. Soc. Med. 44: 552.Google Scholar
  26. Coyle, P. K., Hirsch, R. L., O’Donnell, P., Brooks, B. R., Cohen, S. R., Johnson, R. T., and Wolinsky, J.S., 1980, Cerebrospinal fluid lymphocyte populations and immune complexes in active multiple sclerosis, Lancet 2: 229.PubMedCrossRefGoogle Scholar
  27. Cremer, N. E., Johnson, K. P., Fein, G., and Litosky, W. H., 1980, Comprehensive viral immunology of multiple sclerosis. II. Analysis of serum and CSF antibodies by standard serologic methods, Arch. Neurol. 37: 610.PubMedCrossRefGoogle Scholar
  28. Crome, I., Hanefeld, F., Patrick, D., and Wilson, J., 1973, Late onset globoid cell leukodystrophy, Brain 96: 841.PubMedCrossRefGoogle Scholar
  29. Dalakas, M. C., and Engel, W. K., 1980, Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy, Ann. Neurol. 37: 637.CrossRefGoogle Scholar
  30. Dau, P. C., Petajan, J. H., Johnson, K. P., Panitch, H. S., and Bornstein, M. B., 1980, Plasmapheresis in multiple sclerosis: Preliminary findings, Neurology 30: 1023.PubMedCrossRefGoogle Scholar
  31. De Moerloose, P., Jeannet, M., Martins-da-Silva, B., Werner-Faure, C., Rohr, J., and Gauthier, G., 1979, Increased frequency of HLA-DRw2 and DRw3 in multiple sclerosis, Tissue Antigens 13: 357.PubMedCrossRefGoogle Scholar
  32. Dowling, P. C., and Cook, S. D., 1981, Role of infection in Guillain-Barré syndrome: Laboratory confirmation of herpes viruses in 41 cases, Ann. Neurol. 9: 44.PubMedCrossRefGoogle Scholar
  33. Dunn, H. G., Lake, B. N., Dolman, C. L., and Wilson, J., 1969, The neuropathy of Krabbe’s infantile cerebral sclerosis (globoid cell leukodystrophy), Brain 92: 329.PubMedCrossRefGoogle Scholar
  34. Eickhoff, K., Kaschka, W., Skuaril, F., Theilkaes, L., and Heipertz, R., 1979, Determination of IgG subgroups in cerebrospinal fluid of multiple sclerosis patients and others, Acta Neural. Scand. 60: 277.CrossRefGoogle Scholar
  35. Ellison, G. W., and Myers, C. N., 1980, Immunosuppressive drugs in multiple sclerosis: Pro and con, Neurology 30: 28.PubMedCrossRefGoogle Scholar
  36. Gonsette, R. E., Delmotte, P., and Demonty, L., 1977, Failure of basic protein therapy for multiple sclerosis, J. Neurol. 216: 27.PubMedCrossRefGoogle Scholar
  37. Grundke-Iqbal, I., and Bornstein, M. B., 1980, Multiple sclerosis: Serum gamma globulin and demyelination in organ culture, Neurology 30: 749.PubMedCrossRefGoogle Scholar
  38. Hagberg, B., Kollberg, H., Sourander, P., and Akesson, H. 0., 1969, Infantile globoid cell leukodystrophy (Krabbe’s disease): A clinical and genetic study of 32 Swedish cases (1955–1967), Neuropediatrics 1: 74.Google Scholar
  39. Hauser, S. L., Ault, K. A., Levin, M. J., Garovoy, M. R., and Weiner, H. L., 1981, Natural killer cell activity in multiple sclerosis, J. Immunol. 127: 1114.PubMedGoogle Scholar
  40. Hauser, S. L., Bresnan, M. J., Reinherz, E. L., and Weiner, H. L., 1982, Childhood multiple sclerosis: Clinical features and demonstration of changes in T cell subsets with disease activity, Ann. Neurol. 11: 463.PubMedCrossRefGoogle Scholar
  41. Herndon, R. M., Rubenstein, I. J., Freeman, J. M., and Mathieson, G., 1970, Light and electromicroscopic observations on Rosenthal fibers in Alexander’s disease and in multiple sclerosis, J. Neuropathol. Exp. Neurol. 29: 524.PubMedCrossRefGoogle Scholar
  42. Hogg, S. E., Kobrin, D. E., and Schoenberg, B. S., 1979, The Guillain-Barr’ syndrome: Epidemiologie and clinical features, J. Chronic Dis. 32: 227.PubMedCrossRefGoogle Scholar
  43. Huddlestone, J. R., and Oldstone, M. B. A., 1979, T suppressor (TG) lymphocytes fluctuate in parallel with changes in the clinical course of patients with multiple sclerosis, J. Immunol. 123: 1615.PubMedGoogle Scholar
  44. Jgarashi, M., Schaumburg, H. H., Powers, J., Kishimoto, Y., Kolodny, E., and Suzuki, K., 1976, Fatty acid abnormality in adrenoleukodystrophy (ALD), J. Neurochem. 26: 851.CrossRefGoogle Scholar
  45. Jacobs, L., O’Malley, J., Freeman, A., and Ekes, R., 1981, Intrathecal interferon reduces exacerbations of multiple sclerosis, Science 214: 1026.PubMedCrossRefGoogle Scholar
  46. Jellinger, K., and Seitelberger, F., 1969, Juvenile form of spongy degeneration of the central nervous system, Acta Neuropathol. (Berlin) 13: 276.CrossRefGoogle Scholar
  47. Jellinger, K., and Weingarten, K., 1961, On the problem of Marchiafava-Bignami syndrome, Wien. Z. Nervenheilk. 18: 308.PubMedGoogle Scholar
  48. Jervis, G. A., 1939, The genetics of phenylpyruvic oligophrenia, J. Ment. Sci. 85: 389.Google Scholar
  49. Jervis, G. A., 1953, Phenylpyruvic oligophrenia: Deficiency of phenylalanine oxidizing system, Proc. Soc. Exp. Biol. Med. 82: 514.PubMedGoogle Scholar
  50. Johnson, K. P., 1980, Cerebrospinal fluid and blood assays of diagnostic usefulness in multiple sclerosis, Neurology 30: 106.PubMedCrossRefGoogle Scholar
  51. Kastrukoff, I. F., McLean, D. R., and McPherson, T. A., 1978, Multiple sclerosis treated with antithymocyte globulin—A five year followup, J. Can Sci. Neurol. 5: 175.Google Scholar
  52. Kennedy, P. G. E., and Lisak, R. P., 1979, A search for antibodies against glial cells in the serum and cerebrospinal fluid of patients with multiple sclerosis and Guillain-Barré syndrome, J. Neurol. Sci. 44: 125.PubMedCrossRefGoogle Scholar
  53. Kies, M. W., Shaw, C. M., Fahlbert, W. J., and Alvord, E. C., 1960, Factors affecting the suppression of allergic encephalomyelitis by homologous brain protein fractions, Ann. Allergy 18: 849.PubMedGoogle Scholar
  54. Kihara, H., Porter, M. T., Fluharty, A. I., Scott, M. I., de la Flor, S. D., Trammell, J. L., and Nakamura, R. N., 1973, Metachromatic leukodystrophy: Ambiguity of heterozygote identification, J. Am. Ment. Defic. 77: 389.Google Scholar
  55. Kimbrough, R. D., 1971, Review of the toxicity of hexachlorophene, Arch. Environ. Health 23:119. Kjaer, M., 1980, Visual evoked potentials in normal subjects and patients with multiple sclerosis, Acta Neurol. Scand. 62: 1.Google Scholar
  56. Knox, W. E., 1972, Phenylketonuria, in: The Metabolic Basis of Inherited Disease ( J. B. Stanbury, J. B. Wyngaarden, and D. S. Fredrickson, eds.), pp. 226–295, McGraw-Hill, New York.Google Scholar
  57. Kurland, L. T., 1970, Epidemiology of multiple sclerosis, in: Handbook of Clinical Neurology, Vol. 9 ( P. J. Vinken and G. W. Bruyn, eds.), pp. 63–84, North-Holland, Amsterdam.Google Scholar
  58. Kurtzke, J. F., 1970, Clinical manifestations of multiple sclerosis, in: Handbook of Clinical Neurology, Vol. 9 ( P. J. Vinken and G. W. Bruyn, eds.), pp. 161–216, North-Holland, Amsterdam.Google Scholar
  59. Kurtzke, J. F., 1980, Epidemiologic contributions to multiple sclerosis: An overview, Neurology 30:61. Leiken, S. L., 1960, Pernicious anemia in childhood, Pediatrics 25: 91.Google Scholar
  60. Leroy, J. G., Van Eisen, A. F., Martin, J. J., Dumon; J. E., Ilulet, A. E., Okada, S., and Navarro, C., 1973, Infantile metachromatic leukodystrophy: Confirmation of a prenatal diagnosis, N. Engl. J. Med. 288: 1365.Google Scholar
  61. Link, H., and Laurenzi, M. A., 1979, Immunoglobulin class and light chain type of oligoclonal bands in CSF in multiple sclerosis determined by agarose gel electrophoresis and immunofixation, Ann. Neurol. 6: 107.PubMedCrossRefGoogle Scholar
  62. Lisak, R. P., 1980, Multiple sclerosis: Evidence for immunopathogenesis, Neurology 30: 99.PubMedCrossRefGoogle Scholar
  63. Lisak, R. P., Zweiman, B., Walters, D., Koprowski, H., and Pleasure, D. E., 1978, Cell-mediated immunity to measles, myelin basic protein, and central nervous system extracts in multiple sclerosis, Neurology 28: 798.PubMedCrossRefGoogle Scholar
  64. Manconi, P. E., Marrosu, M. G., Cianchette, C., Ennas, M. G., Manconi, A., and Zaccheo, D., 1980, Lymphocyte subpopulations in cerebrospinal fluid and peripheral blood in multiple sclerosis, Acta Neurol. Scand. 62: 165.Google Scholar
  65. Mastaglia, F. L., and Cala, L. A., 1980, Computed tomography of the brain in multiple sclerosis, Trends Neuroses. 3: 16.Google Scholar
  66. McAlpine, D., Lumsden, C. E., and Acheson, E. D., 1972, Multiple Sclerosis, A Reappraisal, Williams & Wilkins, Baltimore.Google Scholar
  67. Merrill, J., Jondal, M., Seelem, J., Ullberg, M., and Siden, A., 1982, Decreased NK killing in patients with multiple sclerosis: An analysis at the level of the single effector cell in peripheral blood and cerebrospinal fluid and relation to the activity of the disease, Clin. Exp. Neurol. 47: 419.Google Scholar
  68. Merritt, H. H., 1973, A Textbook of Neurology, I.ea & Febiger, Philadelphia.Google Scholar
  69. Merritt, H. H., and Weisman, A. D., 1945, Primary degeneration of the corpus callosum (Marchiafava Bignami’s disease), J. Neuropathol. Exp. Neurol. 4: 155.CrossRefGoogle Scholar
  70. Moser, H. W., 1972, Sulfatide lipidosis: Metachromatic leukodystrophy, in: The Metabolic Basis of Inherited Disease ( J. B. Stanbury, J. B. Wyngaarden, and D. S. Fredrickson, eds.), pp. 688–729, McGraw-Hill, New York.Google Scholar
  71. Neighbour, A. P., Miller, A. E., and Bloom, B. R., 1981, Interferon responses of leucocytes in multiple sclerosis, Neurology 31: 561.PubMedCrossRefGoogle Scholar
  72. Nelson, D. B., Holman, R., Hurwitz, E., Schonberger, L. B., Bregman, D. S., and Kaslow, R. A., 1979, Results of the national surveillance for Guillain-Barré syndrome Neurology 29:1029.Google Scholar
  73. Nielsen, V. K., Paulson, O. B., Rosenkvist, J., Holsoe, E., and Lefvert, A. K., 1982, Rapid improvement of myasthenia gravis after plasma exchange, Ann. Neurol. 11:160.PubMedCrossRefGoogle Scholar
  74. Norenber.g, M. D., Leslie, K. O., and Robertson, A. S., 1982, Association between rise in serum sodium and central pontine myelinolysis, Ann. Neurol. 11: 128.PubMedCrossRefGoogle Scholar
  75. Noronha, A. B. C., Richman, D. P., and Amason, B. G. W., 1980, Detection of in vivo stimulated cerebrospinal fluid lymphocytes by flow cytometry in patients with multiple sclerosis, N. Engl. J. Med. 303: 713–717.PubMedCrossRefGoogle Scholar
  76. Nyland, H., Matre, R., and Mork, S., 1981, Immunological characterization of sural nerve biopsies from patients with Guillain-Barré syndrome Arm. Neurol. 9:80.Google Scholar
  77. Oger, J. J.-R., Fauchet, R., Genetet, B., and Sabouraud, 0., 1980, Evidence for two HLA phenotypes in multiple sclerosis modulating the expression of HLA linked susceptibility to the disease, Neurology 30: 399.Google Scholar
  78. Opelz, G., Terasaki, P., Myers, L., Ellison, G., Ebers, G., Zabriskie, J., Weiner, H., Kempe, II., and Sibley, W., 1977, The association of HLA antigens A3, B7 and DW2 with 330 multiple sclerosis patients in the United States, Tissue Antigens 9: 54.PubMedCrossRefGoogle Scholar
  79. Osterman, P. 0., Fagius, J., Säfwenberg, J., Danersund, A., Wallin, G., and Nordesjö, L. 0., 1982, Treatment of the Guillain-Barré syndrome by plasmaphcresis Arch. Neural. 39:148.Google Scholar
  80. Panitch, H. S., Hooper, C. J., and Johnson, K. P., 1980, CSF antibody to myelin basic protein: Measurement in patients with multiple sclerosis and subacute sclerosing panencephalitis, Arch. Neurol. 37: 206.PubMedCrossRefGoogle Scholar
  81. Pepose, J. S., 1982, A theory of virus-induced demyelination in the Landry-Guillain-Barré syndrome J. Neural. 227:93.Google Scholar
  82. Plum, F., and Posner, J. B., 1972 Stupor and ComaF. A. Davis, New York.Google Scholar
  83. Plum, F., Posner, J. B., and Hain, P. F., 1962, Delayed neurological deterioration after anoxia Arch. Intern. Med. 110:18.Google Scholar
  84. Porter, M. T., Fluharty, A. L., and Kihara, H., 1971, Correction of abnormal cerebroside sulfate metabolism in cultured metachromatic leukodystrophy fibroblasts, Science 172:1263.Google Scholar
  85. Poser, S., Bauer, 11. J., and Poser, W., 1982, Prognosis of multiple sclerosis: Results from an epidemiologic area in Germany, Acta Neural. Scand. 65:347.CrossRefGoogle Scholar
  86. Poskanzer, D., and Adams, R. D., 1974, Multiple sclerosis and the demyelinating diseases, in: Harrison’s Principles of Internal Medicine ( M. M. Wintrobe, G. W. Thorn, R. D. Adams, E. Braunwald, K. J. Isselbacher, and R. G. Petersdorf, eds.), pp. 1815–1821, McGraw-Hill, New York.Google Scholar
  87. Powers, J. M., and Schaumburg, H. H., 1974, Adreno-leukodystrophy (sex-linked Schilder’s disease): A pathogenetic hypothesis based on ultrastructural lesions in adrenal cortex, peripheral nerve and testis, Am. J. Pathol. 76: 481.Google Scholar
  88. Prineas, J., 1970, Polyneuropathies of undetermined cause Acta Neurol. Scand. Suppl. 44:1.Google Scholar
  89. Raine, C. S., Snyder, D. H., Stone, S. H., and Bornstein, M. B., 1977, Suppression of acute and chronic experimental allergic encephalomyelitis in Strain 13 guinea pigs: A clinical and pathological study, J. Neurol. Sci. 31: 355.PubMedCrossRefGoogle Scholar
  90. Richardson, E. P., 1970, Progressive multifocal leukoencephalopathy, in: Handbook of Clinical Neurology, Vol. 9 ( P. J. Vinken and G. W. Bruyn, eds.), pp. 485–499, North-Holland, Amsterdam.Google Scholar
  91. Reinherz, E. L., Weiner, H. L., Hauser, S. L., Cohen, J. A., Distaso, J. A., and Schlossman, S. F., 1980, Loss of suppressor T cells in active multiple sclerosis, N. Engl. J. Med. 303:125.Google Scholar
  92. Sadovnick, A. D., and MacLeod, P. M. S., 1981, The familial nature of multiple sclerosis: Empiric recurrence risks for first, second and third degree relatives of patients, Neurology 31: 1039.PubMedCrossRefGoogle Scholar
  93. Saida, T., Saida, K., Lisak, R., Brown, M. S., Silberberg, D. H., and Asbury, A. K., 1982, In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome, Ann. Neurol. 11: 69.Google Scholar
  94. Salk, J., Romine, J. S., Westall, F. C., and Wiederholt, W. C., 1980, Myelin basic protein studies in experimental allergic encephalomyelitis and multiple sclerosis: A summary with theoretical considerations of multiple sclerosis etiology, in: The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis ( A. N. Davison and M. L. Cuzner, eds.), pp. 141–156, Academic Press, New York.Google Scholar
  95. Santoli, D., Moretta, L., Lisak, R., Gilden, D., and Koprowski, H., 1978, Imbalances in T cell subpopulations in multiple sclerosis patients, J. Immunol. 120: 1369.PubMedGoogle Scholar
  96. Schauf, E. L., Pencek, T. L., Davis, F. A., and Rooney, M. W., 1981, Physiologic basis for neuroelectric blocking activity in multiple sclerosis, Neurology 31: 1338.CrossRefGoogle Scholar
  97. Schaumburg, H. H., Powers, J. M., Raine, C. S., Suzuki, K., and Richardson, E. P., Jr., 1975, Adreno-leukodystrophy: A clinical and pathological study of seventeen cases, Arch. Neurol. 33: 577.CrossRefGoogle Scholar
  98. Scheinberg, L. C., Holland, N. J., Kirschenbaum, M., Oaklander, A., and Geronemus, D. F., 1981, Comprehensive long-term care of patients with multiple sclerosis, Neurology 31: 1121.PubMedCrossRefGoogle Scholar
  99. Schmid, G., Thomas, G., Hempel, K., and Grtininger, W., 1974, Radioimmunological determination of myelin basic protein (MBP) and MBP antibodies, Eur. Neurol. 12: 173.PubMedCrossRefGoogle Scholar
  100. Schooneman, F., Janot, C., Streiff, F., Gerald, A., Dureux, J. B., Canton, P., Roche, G., and Aubrun, P., 1981, Plasma exchange in Guillain-Barré syndrome: Ten cases, Plasmatherapy 2: 117.Google Scholar
  101. Schumacher, G. A., Beebe, G., Kibler, R. F., Kurland, L. T., Kurtzke, J. F., McDowell, T., Nagler, B., Sibley, W. A., Tourtellotte, W. W., and Wilman, T. L., 1965, Problems of experimental trials of therapy in multiple sclerosis, Ann. N. Y. Acad. Sci. 122: 552.CrossRefGoogle Scholar
  102. Sears, E. S., Tindall, R. S. A., and Zarnow, H., 1978, Active multiple sclerosis: Enhanced computerized tomographic imaging of lesions and the effect of corticosteroids, Arch. Neurol. 35: 426.PubMedCrossRefGoogle Scholar
  103. Sheremata, W., Wood, D. D., Moscarello, A. A., and Cosgrove, J. B. R., 1978, Sensitization to myelin basic protein in attacks of multiple sclerosis, J. Neurol. Sci. 36: 165.PubMedCrossRefGoogle Scholar
  104. Shuman, R. A., Leech, R. W., and Alvord, E. C., 1975, Neurotoxicity of hexachlorophene in humans, Arch. Neurol. 32: 320.PubMedCrossRefGoogle Scholar
  105. Sibley, W. A., 1970, Drug treatment of multiple sclerosis, in: Handbook of Clinical Neurology, Vol. 9 ( P. J. Vinken and G. W. Bruyn, eds.), pp. 383–407, North-Holland, Amsterdam.Google Scholar
  106. Slater, R. J., 1980a, Comprehensive long-term care for multiple sclerosis patients, Neurology 30: 37.PubMedCrossRefGoogle Scholar
  107. Slater, R. J., 1980b, A model of care: Matching human services to patient needs, Neurology 30: 39.PubMedCrossRefGoogle Scholar
  108. Stam. F. C., 1970, Megalencephalic type of congenital leukodystropy, in: Handbook of Clinical Neurology, Vol. 10 ( P. J. Vinken and G. W. Bruyn, eds.), pp. 94–102, North-Holland, Amsterdam.Google Scholar
  109. Steinberg, D., 1972, Phytanic acid storage disease: Refsum’s syndrome, in: The Metabolic Basis of Inherited Disease (J. B. Stanbury, J. B. Wyngaarden, and D. S. Fredrickson, eds.), pp. 833–853, McGraw-Hill, New York.Google Scholar
  110. Stumpf, D., and Austin, J. H., 1971, Metachromatic leukodystrophy (MLD). IX. Qualitative and quantitative differences in urinary arylsulfatase A in different forms of MLD, Arch. Neurol. 24: 117.PubMedCrossRefGoogle Scholar
  111. Suzuki, K., 1983, Biochemistry of adrenoleukodystrophy: A review, in: International Symposium on Leukodystrophy and Allied Diseases (T.Yonezawa,ed.), pp. 239–246, Jap. Soc. Neuropath., Kyoto.Google Scholar
  112. Suzuki, K., and Suzuki, Y., 1972, Galactosyl ceramide lipidosis: Globoid cell leukodystrophy (Krabbe’s disease), in: The Metabolic Basis of Inherited Disease (J. B. Stanbury, J. B. Wyngaarden, and D. S. Fredrickson, eds.), pp. 760–783, McGraw-Hill, New York.Google Scholar
  113. Suzuki, Y., Mizumo, Y., 1974, Juvenile metachromatic leukodystrophy: Deficiency of an arylsulfatase A component, J. Pediatr. 85: 823.PubMedCrossRefGoogle Scholar
  114. Tourtellotte, W. W., 1970, Cerebrospinal fluid in multiple sclerosis, in: Handbook of Clinical Neurology, Vol. 9 ( P. J. Vinken and G. W. Bruyn, eds.), pp. 324–382, North-Holland, Amsterdam.Google Scholar
  115. Tourtellotte, W. W., Potvin, A. R., Fleming, J. O., Murtha, K. N., Levy, J., Syndulko, K., and Potvin, S. H., 1980, Multiple sclerosis Measurement and validation of central nervous system IgG synthesis rate, Neurology 30: 240.PubMedCrossRefGoogle Scholar
  116. Traugott, U., and Raine, C. S., 1981, Anti-oligodendrocyte-antibodies in cerebrospinal fluid of multiple sclerosis and other neurologic diseases, Neurology 31: 695.PubMedCrossRefGoogle Scholar
  117. Traugott, U., Snyder, D. S., and Raine, C. S., 1979a, Oligodendrocyte staining by multiple sclerosis serum in non-specific, Ann. Neurol. 6: 13.PubMedCrossRefGoogle Scholar
  118. Traugott, U., Scheinberg, L. C., and Raine, C. S., 1979b, Multiple sclerosis:Circulating antigen-reactive lymphocytes, Ann. Neurol. 6: 425.PubMedCrossRefGoogle Scholar
  119. Traugott, U., Scheinberg, L. C., and Raine, C. S., 1981, Lymphocyte responsiveness to oligodendrocytes in multiple sclerosis, J. Neuroimmunol. 1: 41.PubMedCrossRefGoogle Scholar
  120. Traugott, U., Reinherz, E. L., and Raine, C. S., 1982, Monoclonal anti-T cell antibodies are applicable to the study of inflammatory infiltrates in the central nervous system, J. Neuroimmunol. 3: 365.PubMedCrossRefGoogle Scholar
  121. Traugott, U., Reinherz, E. L., and Raine, C. S., 1983, Multiple sclerosis: Distribution of T cell subsets within active chronic lesions, Science 219: 308.Google Scholar
  122. Tsukamoto, T., Ebina, T., Takase, S., Itahara, K., and Ishida, N., 1982, Increased frequency of lymphocytotoxic antibodies in patients with multiple sclerosis correlated with disease activity, Tohoku J. Exp. Med. 136: 121.PubMedCrossRefGoogle Scholar
  123. Tyler, H. R., 1968, Pelizaeus-Merzbacher disease: A clinical study, Arch. Neurol. Psychiatry 80: 162.CrossRefGoogle Scholar
  124. Vartdal, F., and Vandvik, B., 1982, Multiple sclerosis: Electrofocussed “bands” of oligoclonal CSF IgG do not carry antibody activity against measles, varicella zoster or rotaviruses, J. Neurol. Sci. 54: 99.PubMedCrossRefGoogle Scholar
  125. Waksman, B. H., 1981, Current trends in multiple sclerosis research, lmmunol. Today 2: 87.CrossRefGoogle Scholar
  126. Watanabe, I., Patel, V., Goebel, H. H., Siakotos, A. N., Zeman, W., DeMyer, W., and Dyer, J. S., 1973, Early lesions of Pelizaeus-Merzbacher disease: Electron microscopic and biochemical study, J. Neuropathol. Exp. Neurol. 32: 313.PubMedCrossRefGoogle Scholar
  127. Weiner, H. L., and Dawson, D. M., 1980, Plasmapheresis in multiple sclerosis: Preliminary study, Neurology 30: 1029.PubMedCrossRefGoogle Scholar
  128. Whitaker, J. N., Lisak, R. P., Bashir, R. M., Fitch, O. H., Seyer, J. M., Krance, R., Lawrence, J. A., Chilen, L. T., and O’Sullivan, P., 1980, Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders, Ann. Neurol. 7: 58.PubMedCrossRefGoogle Scholar
  129. Williams, A. C., Mingioli, E. S., McFarland, H. F., Tourtellotte, W. W., and McFarlin, D. E., 1978, Increased CSF IgM in multiple sclerosis, Neurology 28: 996.CrossRefGoogle Scholar
  130. Williams, A. C., Eldridge, H., McFarland, H., Houff, S., Krebs, H., and McFarlin, D., 1980, Multiple sclerosis in twins, Neurology 30: 1139.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • Ute Traugott
    • 1
    • 2
  • Cedric S. Raine
    • 1
    • 2
  1. 1.Department of Pathology (Neuropathology), The Saul R. Korey Department of Neurology, Department of NeuroscienceAlbert Einstein College of MedicineThe BronxUSA
  2. 2.The Rose F. Kennedy Center for Research in Mental Retardation and Human DevelopmentAlbert Einstein College of MedicineThe BronxUSA

Personalised recommendations